Corneal Graft Rejection - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Corneal Graft Rejection - Pipeline Review, H1 2016', provides an overview of the Corneal Graft Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corneal Graft Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Corneal Graft Rejection and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Corneal Graft Rejection - The report reviews pipeline therapeutics for Corneal Graft Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Corneal Graft Rejection therapeutics and enlists all their major and minor projects - The report assesses Corneal Graft Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Corneal Graft Rejection Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Corneal Graft Rejection - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Corneal Graft Rejection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Corneal Graft Rejection Overview 6 Therapeutics Development 7 Pipeline Products for Corneal Graft Rejection - Overview 7 Corneal Graft Rejection - Therapeutics under Development by Companies 8 Corneal Graft Rejection - Pipeline Products Glance 9 Late Stage Products 9 Early Stage Products 10 Corneal Graft Rejection - Products under Development by Companies 10 Corneal Graft Rejection - Companies Involved in Therapeutics Development 11 Circadian Technologies Limited 11 Gene Signal International SA 12 Oxford BioMedica Plc 13 Santen Pharmaceutical Co., Ltd. 14 Corneal Graft Rejection - Therapeutics Assessment 15 Assessment by Monotherapy Products 15 Assessment by Target 16 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 24 aganirsen - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 cyclosporine - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Cyndacel-M - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 GB-301 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 OXB-202 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Stromal Cell Therapy for Corneal Graft Rejection - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 VGX-100 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Corneal Graft Rejection - Recent Pipeline Updates 37 Corneal Graft Rejection - Dormant Projects 41 Corneal Graft Rejection - Product Development Milestones 42 Featured News & Press Releases 42 Jan 30, 2012: VGX-100 Identified As Potential New Therapy For Improving Corneal Graft Survival 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44
List of Tables
Number of Products under Development for Corneal Graft Rejection, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Products under Development by Companies, H1 2016 10 Corneal Graft Rejection - Pipeline by Circadian Technologies Limited, H1 2016 11 Corneal Graft Rejection - Pipeline by Gene Signal International SA, H1 2016 12 Corneal Graft Rejection - Pipeline by Oxford BioMedica Plc, H1 2016 13 Corneal Graft Rejection - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 14 Assessment by Monotherapy Products, H1 2016 15 Number of Products by Stage and Target, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Corneal Graft Rejection Therapeutics - Recent Pipeline Updates, H1 2016 37 Corneal Graft Rejection - Dormant Projects, H1 2016 41
List of Figures
Number of Products under Development for Corneal Graft Rejection, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Assessment by Monotherapy Products, H1 2016 15 Number of Products by Targets, H1 2016 16 Number of Products by Stage and Targets, H1 2016 16 Number of Products by Mechanism of Actions, H1 2016 18 Number of Products by Stage and Mechanism of Actions, H1 2016 18 Number of Products by Routes of Administration, H1 2016 20 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Molecule Types, H1 2016 22 Number of Products by Stage and Molecule Types, H1 2016 22
Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive tRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving creamRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmaceRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.